title: Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.
abstract: G protein signaling through human somatostatin receptor subtype 2 (SSTR2) is well known, but the amino acids involved in stimulation of intracellular responses upon ligand binding have not been characterized. We constructed a series of point mutants in SSTR2 at amino acid positions 89, 139, and 140 in attempts to disrupt G protein signaling upon ligand binding. The aspartic acid changes at position 89 to either Ala, Leu, or Arg generated mutant receptors with varying expression profiles and a complete inability to bind somatostatin-14 (SST). Mutations to Asp 139 and Arg 140 also led to varying expression profiles with some mutants maintaining their affinity for SST. Mutation of Arg 140 to Ala resulted in a mutated receptor that had a B(max) and dissociation constant (K(d)) similar to wild-type receptor but was still coupled to the G protein as determined in both a cAMP assay and a calcium-release assay. In contrast, mutation of Asp 139 to Asn resulted in a mutated receptor with B(max) and K(d) values that were similar to wild type but was uncoupled from G protein-mediated cAMP signaling, but not calcium release. Thus, we identified mutations in SSTR2 that result in either receptor expression levels that are similar to wild type but is completely ablated for ligand binding or a receptor that maintains affinity for SST and is uncoupled from G protein-mediated cAMP signaling.
authors.affiliation: Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri 63108-8224, USA.
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Parry
authors.forename: Ronald
authors.initials: R
authors.lastname: Chen
authors.forename: Rebecca
authors.initials: R
authors.lastname: Andrews
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Lears
authors.forename: Buck E
authors.initials: BE
authors.lastname: Rogers
mesh_terms: D000409:Alanine / Q000235:genetics / Q000378:metabolism; D019943:Amino Acid Substitution; D000596:Amino Acids / Q000235:genetics / Q000378:metabolism*; D001120:Arginine / Q000235:genetics / Q000378:metabolism; D001224:Aspartic Acid / Q000235:genetics / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D001667:Binding, Competitive; D002118:Calcium / Q000378:metabolism; D045744:Cell Line, Tumor; D000242:Cyclic AMP / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D019204:GTP-Binding Proteins / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D007700:Kinetics; D007930:Leucine / Q000235:genetics / Q000378:metabolism; D017354:Point Mutation; D011485:Protein Binding; D011869:Radioligand Assay; D017481:Receptors, Somatostatin / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D013004:Somatostatin / Q000378:metabolism
chemical_list: D000596:Amino Acids; D017481:Receptors, Somatostatin; D001224:Aspartic Acid; D013004:Somatostatin; D001120:Arginine; C093733:somatostatin receptor 2; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D007930:Leucine; D000409:Alanine; D002118:Calcium